Home   HELP  /   AYUDA  /   求助 : help-desk@bctrials.org  /   (415) 476-5777 Click to print page  Print

Browse Trials


In response to COVID-19, some breast cancer trials have temporarily stopped enrolling new patients. Use the contact information in our trial listings to call or email the research site for information about a trial's status.

Visit COVID-19 & Cancer Clinical Trials on Metastatic Trial Talk for regularly updated information about clinical trials during the coronavirus pandemic.


Currently viewing trials
(Last updated: October 24, 2020)

Zip Code:
 

Narrow my choices:

Radius (miles): All U.S.

20 All U.S.
Early stage    Advanced 
Treatment    Non-treatment 
Phase    I     II     III 
Display Only New Trials 
 
Close
Treatment

BRCA1/2 (inherited)

Chemotherapy

Hormone Therapy

Radiation Oncology

Surgery

Surgery: Reconstruction

Targeted Therapy: All

Targeted Therapy: Anti-HER2 Therapy

Targeted Therapy: CDK Inhibitors

Targeted Therapy: PARP Inhibitors

Targeted Therapy: Tumor Mutations

Targeted Therapy: Other Targeted Therapy

Vaccines and Immunotherapy

Other Treatment

Non-Treatment

Activities

Complementary and Alternative Medicine

Decision Support

Diagnosing Breast Cancer

Genetics/Family History

Having Children

Lymphedema

Managing Side Effects

No Travel Required

Predicting Response to Treatment

Preventing Breast Cancer

Preventing Recurrence

Screening

Support/Education

Surveys/Interviews/Registries

Close

AKT

ALK

AR

BARD1

BRCA1/2 (tumor)

BRIP1

CD205

CD70

CHEK2 or CHEK1

ESR1

FGFR

HER2/ERBB2

HLA

MET or C-Met

NTRK

PALB2

PIK3CA or PI3K

PTEN

RAD51

RAF (including BRAF)

RAS (KRAS or NRAS)

RB

ROS1

TP53

1

NEAREST SITE: 2434 miles
Lombardi Comprehensive Cancer Center
Washington,DC

VISITS: 3 visits per month, ongoing

PHASE: I

NCT ID: NCT03854903

Ibrance, Bosutinib & Fulvestrant for Advanced HR+ HER2- Breast Cancer

A Phase I Trial of Palbociclib and Bosutinib With Fulvestrant in Patients With Metastatic Hormone Receptor Positive and HER2 Negative (HR+ HER2-) Breast Cancer Refractory to an Aromatase Inhibitor and a CDK4/6 Inhibitor Scientific Title

Purpose
To evaluate the safety, best dose and effects (good and bad) of bosutinib (Bosulif®) when it is used along with palbociclib (Ibrance®) and fulvestrant (Faslodex®).
Who is this for?
Women with estrogen receptor positive, HER2 negative advanced (some stage III) or metastatic (stage IV) breast cancer, who have had no more than 3 chemotherapy regimens, and have been treated with at least one aromatase inhibitor and one CDK 4/6 inhibitor.    Full eligibility criteria
Contact research site
Close

Contact Research Sites

  • What's involved?
  • What's being studied?
  • How can I learn more?
  • <p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Palbociclib (Ibrance®), by mouth, daily, 3 weeks on, 1 week off</li> <li class="seamTextUnorderedListItem">Bosutinib (Bosulif®), by mouth, 5 days on, 2 days off</li> <li class="seamTextUnorderedListItem">Fulvestrant (Faslodex®), by injection, 3 times a month, ongoing</li></ul>
  • <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Bosulif is a targeted therapy approved to treat certain types of leukemia. Its use in breast cancer is considered experimental. </li> <li class="seamTextUnorderedListItem">Ibrance is a targeted therapy approved to treat metastatic breast cancer in combination with Faslodex or letrozole (Femara®), which are both hormone therapies.</li></ul>
  • <ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03854903' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.gov/publications/dictionaries/cancer-drug/def/bosutinib' target='_blank'>NCI Drug Dictionary: Bosutinib</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/2018/08/01/mbc-news/' target='_blank'>Metastatic Trial Talk.org: Update on CDK Inhibitors</a> </li></ul>
See more